- Home
- DMA vs ASRT Comparison
DMA vs ASRT Comparison
Compare DMA & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMA | ASRT |
|---|---|---|
| Founded | N/A | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.4M | 76.0M |
| IPO Year | 2011 | 2004 |
Fundamental Metrics
Financial Performance| Metric | DMA | ASRT |
|---|---|---|
| Price | $8.40 | $12.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 43.4K | 33.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 95.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $124,961,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.17 | $0.51 |
| 52 Week High | $9.15 | $12.95 |
Technical Indicators
Market Signals| Indicator | DMA | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 32.10 | 60.93 |
| Support Level | $8.31 | $0.67 |
| Resistance Level | $8.87 | $12.75 |
| Average True Range (ATR) | 0.19 | 0.52 |
| MACD | -0.01 | -0.18 |
| Stochastic Oscillator | 24.53 | 77.29 |
Price Performance
Historical ComparisonAbout DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.